Global Hospital Acquired Disease Testing Market to Reach Worth Usd 1.6 Bn by 2022: Credence Research

According to the latest report published by Credence Research, Inc. “Hospital Acquired Disease Testing: Market Growth, Future Prospects and Competitive Analysis, 2016-2022,” the hospital acquired disease testing market was valued at USD 523.0 Mn in 2015, and is expected to reach USD 1,630.0 Mn by 2022, expanding at a CAGR of 5.4% from 2016 to 2022.

Browse the full report Hospital Acquired Disease Testing: Market Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/hospital-acquired-disease-testing-market

Market Insights

Hospital acquired infections/diseases (HAIs) or nosocomial infections are defined to the infection acquired by patients during their stay in healthcare settings. Approximately 9.2 out of 100 patients in the U.S. acquire HAI. The most common types of HAIs include pneumonia, urinary tract infection, bloodstream infection, surgical site infection and others. HAIs are caused by pathogens among patients with compromised immune system, and negligence by hospital staff. The significant morbidity and mortality, the associated management costs and growing pressure from governing bodies have urged care-givers to devise accurate diagnosis of HAIs for efficient healthcare provision.

Browse All Reports of This Category @ http://www.credenceresearch.com/industry/pharmaceuticals-market

The global hospital acquired disease testing market is categorized into tests for hospital acquired pneumonia, urinary tract infection, surgical site infection, bloodstream infection, MRSA and others. Hospital acquired pneumonia and urinary tract infection together occupy more over 50% market share in 2015 with a larger set of revenue coming from urinary tract infection. The prevalence and morbidity associated with urinary tract infection is the highest among the other infection types and its diagnosis is the swiftest. It is anticipated that the dominance of this...